PHIL.MI
Strong BuyFull HouseAI neutralPhilogen S.p.A. · Healthcare · Italy · $1.0B
EUR 22.25 +0.0% · close 7 Oct · scored 9 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on PHIL.MI (May 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Philogen is an Italian clinical-stage biotechnology firm developing targeted antibody-cytokine conjugates and small-molecule therapeutics for oncology. A recent 40% upward revision in consensus earnings estimates highlights positive milestone progress and operational delivery in licensing partnerships. Nevertheless, commercial-stage revenue remains dependent on binary Phase III trial outcomes and partner commercialization timelines, leaving the business model exposed to classic drug development pipeline volatility rather than durable, predictable owner earnings.
ABOUT PHILOGEN S.P.A.
Read
Philogen S.p.A. is a clinical-stage biotechnology company specializing in the discovery and development of targeted biopharmaceuticals, particularly antibody-drug conjugates (ADCs) for cancer and chronic inflammatory diseases. The company's competitive moat is its proprietary DNA-encoded chemical libraries and antibody-based targeting platforms. Philogen operates as a high-tech niche player with a robust pipeline and strategic partnerships with global pharmaceutical giants.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.7M | 23.1M | 74.0M | 314.3M | 136.7% | 317.3M | 79.4M | 42.6M | -63.2% |
| EPS (EUR) | -0.13 | -0.15 | 1.12 | 5.70 | 409.1% | 5.62 | — | — | — |
| Shares | 40.4M | 40.3M | 40.3M | 40.3M | -0.3% | — | — | — | — |
| Debt | 11.9M | 12.1M | 11.5M | 10.9M | -2.9% | 11.5M | — | — | — |
| Equity | 97.9M | 90.6M | 138.7M | 373.9M | 56.3% | — | — | — | — |
| Op CF | -4.9M | -4.8M | 40.8M | 268.0M | 556.1% | 266.1M | — | — | — |
| Inv CF | 24.2M | 0.2M | -22.3M | -168.3M | — | — | — | — | — |
| Fin CF | -3.8M | -4.2M | -3.8M | -3.0M | — | — | — | — | — |
Calmer than 82% of stocks we rank over the past year (25% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PHIL.MI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PHIL.MI | Philogen S.p.A.(you) | $1.0B | 100 | Strong Buy |
| SFL.MI | Safilo Group S.p.A. | $786M | 95 | Strong Buy |
| NWRN.SW | Newron Pharmaceuticals S.p.A. | $279M | 6 | Strong Sell |
| ELN.MI | EL.En. S.p.A. | $1.4B | 85 | Strong Buy |
| GNTA | Genenta Science S.p.A. | $55M | 28 | Sell |
| GHC.MI | Garofalo Health Care S.p.A. | $542M | 78 | Buy |
| PHN.MI | Pharmanutra S.p.A. | $771M | 71 | Buy |
| DIA.MI | DiaSorin S.p.A. | $4.4B | 84 | Strong Buy |
| AMP.MI | Amplifon S.p.A. | $3.6B | 78 | Buy |
| GPI.MI | GPI S.p.A. | $474M | 61 | Hold |
Peer medians: ROE 9.1% · P/E 25.2x · Gross margin 50.3%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.